Blood-brain barrier disruption (BBBD) is a consequence of ischemia and may also exacerbate damage to brain parenchyma. Therefore, maintaining BBB integrity is critical for the central nervous system (CNS) homeostasis.

2019年4月11日 · We propose BBBD mapping as a valuable tool for detection of subtle brain ischemia and a promising predictive biomarker required for risk stratification and stroke prevention.

Blood-brain-barrier disruption (BBBD) aims to compromise transiently the BBB using chemical or mechanical means to allow the passage of circulating therapeutic molecules and biomarkers into, and less frequently, out of the parenchyma (Table 1).

2018年6月1日 · We studied early BBBD in mice after transient middle cerebral artery occlusion by multimodal, high-field (9.4T) in vivo magnetic resonance imaging, including the contrast agent gadofluorineM as an albumin-binding tracer.

2020年9月18日 · A single-arm Phase I trial demonstrated BBBD by dynamic contrast-enhanced MRI (DCE-MRI) using MRgFUS in high-grade glioma (HGG) patients . Although BBBD was demonstrated in the completed Phase I trial by gadolinium enhancement seen on DCE-MRI, the extravasation of chemotherapy can only be accurately measured through serum biomarkers.

Importance: Blood-brain barrier disruption (BBBD) is a systemic therapy for malignant central nervous system (CNS) tumors that has been linked to poorly understood pigmentary maculopathy. Objectives: To examine the rate of and risk factors for the development of BBBD-associated maculopathy and to assess whether there can be visually significant ...

Osmotic blood-brain barrier disruption (BBBD) therapy was first introduced in the early 1980s as a method to increase the penetration of chemotherapeutics into the central nervous system (CNS). 1,2 The procedure involves intra-arterial injection of a warmed, hypertonic mannitol solution to disrupt the tight junctions of vascular endothelial ...

An axial T1 Gd-DTPA enhanced MRI immediately after BBBD is analyzed using an exposition map translating the area under the curve (AUC). In this animal in which the intensity of the BBBD was moderate at best, the right hemisphere present a slight change in signal intensity (a).

These findings suggest that BBBD is a promising therapy for PCNSL, especially for patients in first line, but also for patients with relapsed or refractory disease after conventional chemotherapy, who commonly have a very poor prognosis. Treatment-related toxicity was generally manageable.

2007年6月20日 · Most chemotherapy regimens for PCNSL use intravenous methotrexate, often in combination with whole brain radiation. We present our multi- institutional experience in the treatment of PCNSL using BBBD in conjunction with Intra-arterial methotrexate (IA …